DAIDS Bethesda, MD USA ARCHIVED POLICY Use of Study Products Not Marketed in the United States Approval Date: 24 JUN 2011 Effective Date: 24 JUN 2011

First Page		Document Content
Date: 2015-01-20 10:50:43 Pharmaceutical industry Pharmacology Clinical research Medical statistics Food and Drug Administration National Institute of Allergy and Infectious Diseases Clinical trial Good manufacturing practice European Medicines Agency Pharmaceutical sciences Health Research		DAIDS Bethesda, MD USA ARCHIVED POLICY Use of Study Products Not Marketed in the United States Approval Date: 24 JUN 2011 Effective Date: 24 JUN 2011 Add to Reading List Source URL: www.niaid.nih.gov Download Document from Source Website File Size: 685,29 KB Share Document on Facebook

	National Institute of Allergy and Infectious Diseases Awards MERS/SARS Coronavirus Drug Research Grant to Autoimmune Technologies FOR IMMEDIATE RELEASE New Orleans, June 24, Autoimmune Technologies LLC, a New Orle DocID: 1uTGp - View Document
	Emerging and Re-emerging Infectious Diseases developed under a contract from the National Institutes of Health in collaboration with the National Institute of Allergy and Infectious Diseases DocID: 1uoM7 - View Document
	Sanaria® PfSPZ Malaria Vaccine Wins 2014 Vaccine Industry Excellence Award for “Best Prophylactic Vaccine” Rockville, MD - Sanaria received the 2014 Vaccine Industry Excellence Award for the “Best Prophylactic Vac DocID: 1rm3H - View Document
	Off i ce O f C l i nic al S it e Oversight National Institute of Allergy and Infectious Diseases (NIAID) MOB Report 4th Edition DocID: 1qxvn - View Document
	Research Conducted and Supported by the National Institutes of Health (NIH) in Addressing Zika Virus Disease. Testimony before the DocID: 1qsO1 - View Document